A biostatistician by training, Chris is an executive leader with the technical and business experience required to lead in the clinical research industry. He held executive and senior leadership roles before MMS, including management of biometrics operations as well as oversight of key customer accounts. His key strengths include his statistical and data expertise, building and maintaining required operational delivery models to ensure quality delivery, implementing effective governance to ensure successful client collaborations and relationships, and providing statistical consultation.  Throughout his career, Chris has been a statistical lead for hundreds of clinical studies, served as a voting member on data monitoring committees, and guided the statistical strategy for regulatory submissions.

I’m grateful to work at a company with such a strong company culture that cares about its colleagues. Being a part of growing the company and developing the business strategies and operational excellence needed to continue our success is exciting and rewarding to me after many years in this space.
Chris Schoonmaker
Chief Operating Officer

As Chief Operating Officer, Chris has global responsibility for operations across all MMS service lines globally as well as business strategies for growth. Chris is responsible for driving corporate operational excellence, including talent planning, productivity improvements and cost management across the organization.

Chris received his Master of Public Health in Epidemiology and Biostatistics from Boston University.

Suggested For You

perspectives

November 21st, 2024

Essential Nonclinical Strategies for Cell and Gene Therapy (CGT) Success

news

November 19th, 2024

MMS Recognized as a Top Workplace by Detroit Free Press and USA Today Network for the Fourth Consecutive Year

perspectives

November 12th, 2024

REMS Logic Modeling: Applying FDA Guidance from November 2024 CDER Webinar

news

November 8th, 2024

MMS Named a Finalist in the 2024 Fierce CRO Awards for Leadership in Regulatory Compliance

perspectives

November 6th, 2024

How to Successfully Manage Rescue Studies and Turn Around Clinical Trials Facing Failure

perspectives

October 29th, 2024

Why Outsourcing QC of Regulatory and Medical Writing Documents is a Competitive Advantage for Large Pharma Companies

perspectives

October 22nd, 2024

Choosing the Right Clinical Trial Design: A Crucial Step in Protocol Development

perspectives

October 15th, 2024

Putting the Action in Diversity Action Plans and the Real-Time Data Visualization Technology Needed to Ensure It Happens

news

October 15th, 2024

MMS Recognized with EcoVadis Bronze Medal for Leadership in ESG Sustainability Efforts as a Leading Clinical Research Organization (CRO)

perspectives

October 8th, 2024

Diversity Action Plan Guidance Part I: Implications for Sponsors

webinar

October 22nd, 2024

Optimal Strategies to Protect Commercially Confidential Information (CCI) in Clinical Documents and Report Trial Results Under Revised EU-CTIS Transparency Rules

perspectives

September 30th, 2024

Meet the Leaders Driving MMS’s European Growth